Tech Company Financing Transactions

Melinta Therapeutics Funding Round

On 6/10/2015, Melinta Therapeutics received $67 million in funding from Malin, private investors and Vatera Healthcare Partners.

Transaction Overview

Announced On
Transaction Type
Venture Equity

Malin (Lead Investor) (Sean Murphy)

Vatera Healthcare Partners (Thomas Koestler)

Proceeds Purpose
Proceeds from the financing will be used to complete the final Phase 3 study of delafloxacin, an investigational fluoroquinolone, currently undergoing a confirmatory Phase 3 study for the treatment of patients with acute bacterial skin and skin structure infections (ABSSSI). Funds will also support the potential submission of a New Drug Application (NDA) for delafloxacin for the lead indication, pursuing new indications for delafloxacin including hospital-treated community-acquired bacterial pneumonia (hCABP), and advancing a lead candidate for the company's ESKAPE pathogen program.

Company Information

Company Status
Private & Independent
Mailing Address
300 George St. 301
New Haven, CT 06511
Email Address
Melinta Therapeutics' mission is to discover, develop and commercialize groundbreaking antibiotics to overcome drug-resistant, life-threatening infections.
Melinta Therapeutics LinkedIn Company Profile
Social Media
Melinta Therapeutics Company Twitter Account
Company News
Melinta Therapeutics News
Melinta Therapeutics on Facebook
Melinta Therapeutics on YouTube

Management Team

Email & Social
Chief Executive Officer
Christine Miller
  Christine Miller LinkedIn Profile  Christine Miller Twitter Account  Christine Miller News  Christine Miller on Facebook
Chief Financial Officer
Peter Milligan
  Peter Milligan LinkedIn Profile  Peter Milligan Twitter Account  Peter Milligan News  Peter Milligan on Facebook
VP - Bus. Development
Michael McGuire
  Michael McGuire LinkedIn Profile  Michael McGuire Twitter Account  Michael McGuire News  Michael McGuire on Facebook
VP - Finance
Susan Blum
  Susan Blum LinkedIn Profile  Susan Blum Twitter Account  Susan Blum News  Susan Blum on Facebook
VP - General Counsel
Jennifer Sanfilippo
  Jennifer Sanfilippo LinkedIn Profile  Jennifer Sanfilippo Twitter Account  Jennifer Sanfilippo News  Jennifer Sanfilippo on Facebook



Browse more venture capital transactions:

Prev: 6/10/2015: Control venture capital transaction
Next: 6/10/2015: Rancher Labs venture capital transaction


Share this article


About Database of VC Transactions

We do our best to document every notable VC transaction. All VC database entries reported here are sourced from company press releases and news coverage. The data comes to us via our partnership with, an affiliated venture.


Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities


Business Glossary